Aura, Attack and Aftermath: Placing CBD Carefully Within UK Migraine Care

Migraine is a neurological condition with a recognisable pattern for many people: an attack may begin with aura, build through hours of pain and nausea, and leave a residue of fatigue that lasts into the following day. In the UK, care usually begins in general practice, with diagnosis based on history and with NHS pathways for acute treatment and prevention. Interest in CBD has grown alongside that conventional care, but the two should not be confused. As of 2026, CBD products sold on the UK high street are generally regulated as food supplements rather than licensed medicines, and no CBD product is authorised to treat migraine. This article is therefore not a recommendation to use CBD. It is a clinical-minded guide to the questions a migraine sufferer should ask before doing so.

Two questions, not one: stopping an attack and reducing frequency

The first distinction to make is between acute relief and prevention. Acute treatment aims to interrupt an attack already under way; preventive treatment aims to reduce how often attacks occur and how severe they become. CBD marketing frequently blurs the two, implying both rapid relief and long-term control without saying which claim is being made. The evidence base does not support either claim with confidence. Published research is limited, often small, and rarely designed to the standard expected of a migraine medicine. There is no large UK randomised trial demonstrating that CBD prevents migraine, and there is no reliable evidence that it aborts an attack in the way a triptan or a simple analgesic might.

That matters because migraine care is not passive. A GP or specialist may review triggers, sleep, hydration, caffeine, hormonal patterns and coexisting anxiety or depression. Preventive medicines such as propranolol, amitriptyline, topiramate or candesartan may be considered, and specialist pathways exist for people who do not respond. CBD might be raised as a complementary consideration, but it should not displace that assessment. Anyone using CBD while also taking prescribed migraine treatment should tell their clinician rather than self-managing in parallel.

Aura, red flags and the limits of self-management

Aura is usually reversible and develops over minutes, often as visual disturbance such as flashing lights, zigzag lines or blind spots. Some people experience sensory changes or difficulty with speech. Not every unusual headache is migraine, however, and CBD has no place in the self-management of an undiagnosed headache. Urgent assessment is needed for a sudden, severe headache that peaks within seconds or minutes; headache with fever, neck stiffness, confusion, weakness, numbness, speech disturbance or visual loss; headache after a head injury; a new headache pattern after the age of 50; headache during pregnancy or the postpartum period; or headache in someone with cancer or a weakened immune system. These are red flags, not reasons to adjust a dropper.

Even in established migraine, a change in pattern deserves review. If aura becomes prolonged, if attacks become more frequent, or if the character of the headache changes, the priority is clinical assessment. CBD should not be used to mask a deterioration or to delay a conversation with a GP.

Medication-overuse headache and the counting trap

One of the more common pitfalls in migraine care is medication-overuse headache. Taking acute pain relief or triptans too frequently can, for some people, increase headache frequency rather than reduce it. The risk is not confined to prescription medicines; any regular acute treatment needs to be counted and reviewed. CBD is not exempt from this discipline. A person may begin using CBD for attacks, then use it more often, then lose sight of how many treatment days they are accumulating each month.

A simple record is more useful than a precise target dose. Note the date and time of each attack, whether aura was present, severity, duration, what acute medicine was taken, what preventive medicine is prescribed, and when CBD was used. Record the product name, batch and stated strength rather than chasing a number on the label. Bring that record to a GP or pharmacist review. The aim is not to prove that CBD works; it is to see whether attacks are changing and whether any treatment, including CBD, is being used too often.

Interactions: triptans, preventives and the liver

CBD is metabolised in the liver and can interact with other medicines. The evidence on specific migraine combinations is limited, but caution is reasonable. Triptans, common preventive medicines, some antidepressants and certain epilepsy medicines may all warrant a conversation with a pharmacist before CBD is added. CBD may also add to the effects of alcohol or sedating medicines. It should not be assumed that a food-supplement label means an absence of pharmacological activity.

This is not a reason for alarm; it is a reason for disclosure. Tell your GP or pharmacist what you are taking, including CBD, and do not stop prescribed migraine treatment in order to try CBD. If you experience new side effects, unusual drowsiness, gastrointestinal upset or a change in mood, seek advice.

Buying in the UK: claims, strength and regulation

UK shoppers should be wary of products that promise to treat migraine or replace prescribed care. CBD food supplements are subject to novel food requirements, and labels should be clear about cannabinoid content and THC limits. A certificate of analysis is useful but does not prove clinical benefit. Choose products with transparent labelling, avoid those making medicinal claims, and keep the packaging for any clinical review.

A careful place, not a first-line answer

CBD may be considered by some migraine sufferers as a complementary option alongside established NHS care, but it is not a substitute for diagnosis, red-flag assessment or prescribed treatment. The responsible position in 2026 is modest: discuss it openly, record it carefully, and keep the clinical pathway in view. If attacks are frequent, changing or disabling, the next step is a review with a healthcare professional, not another bottle.